Is it safe to start or continue a benzodiazepine in a patient with an acute upper respiratory infection, particularly if they have asthma, COPD, sleep‑disordered breathing, or are elderly?

Benzodiazepines and Upper Respiratory Illness: Safety Considerations

Benzodiazepines should generally be avoided or used with extreme caution in patients with acute upper respiratory infections, particularly in those with underlying respiratory disease (COPD, asthma), sleep-disordered breathing, or advanced age, due to significant risks of respiratory depression and adverse outcomes.

Key Safety Concerns

The primary concern with benzodiazepines during acute respiratory illness stems from their dose-dependent respiratory depressant effects. Benzodiazepines depress the central ventilatory response to both hypoxia and hypercapnia 1. This becomes particularly dangerous when:

• Combined with opioids (synergistic respiratory depression occurs in 92% of subjects with apnea in 50%) 2
• Used in patients with underlying respiratory disease
• Administered in elderly or debilitated patients who require dose reductions 1

High-Risk Populations

COPD Patients

The evidence is particularly concerning for COPD patients:

• New benzodiazepine use increases risk of outpatient respiratory exacerbations by 45% (RR 1.45) and emergency room visits for COPD or pneumonia by 92% (RR 1.92) within 30 days 3
• Benzodiazepines are associated with increased risk of respiratory failure, with recent use showing an OR of 28.6 for acute respiratory failure 4, 5
• Long-term benzodiazepine use may limit the benefits of respiratory support interventions 6

Asthma Patients

Current benzodiazepine use increases asthma exacerbation risk by 49% (OR 1.49) and is associated with nearly 3-fold increased mortality following exacerbation (HR 2.78) 7. This represents a clear contraindication in acute asthma presentations.

Sleep-Disordered Breathing

Patients with obstructive sleep apnea face particularly high risks, with benzodiazepines increasing acute respiratory failure risk substantially 4. The 2016 ESC Heart Failure Guidelines note that sleep-disordered breathing occurs in over one-third of patients with respiratory conditions 8.

Elderly Patients

Dose reductions of 20% or more are required for patients over 60 years 1. The elderly experience higher rates of central nervous system side effects and respiratory complications, with parenteral formulations showing significantly increased risk (OR 7.63-10.17 for any adverse events) 9.

Clinical Decision Algorithm

For patients with acute upper respiratory infection:

1. If patient has COPD, asthma, or known sleep apnea: Avoid benzodiazepines entirely; consider non-benzodiazepine alternatives for anxiety or insomnia (e.g., melatonin, trazodone, doxepin) 10

2. If patient is elderly (>60 years) with URI: Avoid if possible; if absolutely necessary, reduce dose by ≥20% and use shortest-acting agent (midazolam preferred over diazepam) 1

3. If patient is on chronic benzodiazepines: Do not abruptly discontinue due to withdrawal risks, but avoid dose escalation during acute illness and monitor closely for respiratory depression

4. If benzodiazepine must be used:

   • Use lowest effective dose
   • Prefer oral over parenteral routes (parenteral routes show 7-10 fold increased adverse event risk) 9
   • Never combine with opioids during acute respiratory illness
   • Ensure close monitoring with pulse oximetry

Special Considerations

Respiratory depression is more likely when:

• Benzodiazepines are combined with opioids (avoid this combination) 1, 2
• Drugs are administered rapidly rather than titrated slowly 2
• Patients have pre-existing hypercapnia or hypoxemia
• Multiple sedating medications are used concurrently

COVID-19 context: During the pandemic, increased benzodiazepine use was associated with deeper sedation, prolonged mechanical ventilation, increased delirium rates, and higher mortality 11. This reinforces that even in severe respiratory illness, benzodiazepines worsen rather than improve outcomes.

End-of-Life Exception

The only clear indication for benzodiazepines in respiratory illness is for palliative sedation in patients with refractory dyspnea in the last days of life 12, 13. Even for chronic breathlessness in advanced illness, benzodiazepines alone show no benefit and are not recommended as first-line therapy 13.

Common Pitfalls to Avoid

• Do not prescribe benzodiazepines for dyspnea relief in non-palliative settings—there is no evidence of benefit and clear evidence of harm 13, 14
• Do not assume non-benzodiazepine hypnotics (Z-drugs) are safer—while some data suggest slightly better profiles, they still carry respiratory risks in COPD 5, 10
• Do not continue benzodiazepines "because the patient is already on them" during acute illness—this is when risks are highest 3, 4